Allylestrenol

	WikiDoc Resources for Allylestrenol
Articles
Most recent articles on Allylestrenol Most cited articles on Allylestrenol Review articles on Allylestrenol Articles on Allylestrenol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Allylestrenol Images of Allylestrenol Photos of Allylestrenol Podcasts & MP3s on Allylestrenol Videos on Allylestrenol
Evidence Based Medicine
Cochrane Collaboration on Allylestrenol Bandolier on Allylestrenol TRIP on Allylestrenol
Clinical Trials
Ongoing Trials on Allylestrenol at Clinical Trials.gov Trial results on Allylestrenol Clinical Trials on Allylestrenol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Allylestrenol NICE Guidance on Allylestrenol NHS PRODIGY Guidance FDA on Allylestrenol CDC on Allylestrenol
Books
Books on Allylestrenol
News
Allylestrenol in the news Be alerted to news on Allylestrenol News trends on Allylestrenol
Commentary
Blogs on Allylestrenol
Definitions
Definitions of Allylestrenol
Patient Resources / Community
Patient resources on Allylestrenol Discussion groups on Allylestrenol Patient Handouts on Allylestrenol Directions to Hospitals Treating Allylestrenol Risk calculators and risk factors for Allylestrenol
Healthcare Provider Resources
Symptoms of Allylestrenol Causes & Risk Factors for Allylestrenol Diagnostic studies for Allylestrenol Treatment of Allylestrenol
Continuing Medical Education (CME)
CME Programs on Allylestrenol
International
Allylestrenol en Espanol Allylestrenol en Francais
Business
Allylestrenol in the Marketplace Patents on Allylestrenol
Experimental / Informatics
List of terms related to Allylestrenol

Allylestrenol
Clinical data
Synonyms	17α-Allylestr-4-en-17β-ol
Pregnancy; category	Used in threatened miscarriage and RPL;
ATC code	G03DC01 (WHO) ;
Identifiers
	IUPAC name (17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol;
CAS Number	432-60-0 ;
PubChem CID	235905;
DrugBank	DB01431 ;
ChemSpider	205855 ;
UNII	I47VB5DZ8O;
KEGG	D01374 ;
ChEMBL	ChEMBL1445549 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H32O
Molar mass	300.48 g/mol
3D model (JSmol)	Interactive image;
	SMILES O[C@]2(CC[C@H]1[C@H]4[C@H](CC[C@@]12C)[C@@H]3\C(=C/CCC3)CC4)C\C=C;
	InChI InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1 ; Key:ATXHVCQZZJYMCF-XUDSTZEESA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Allylestrenol (BAN/INN), also known as allyloestrenol and allyl estrenol, is a synthetic progestogen used to prevent threatened miscarriage, recurrent pregnancy loss and premature labor.^[1]^[2] In men, it has also been studied as a treatment for benign prostatic hyperplasia, with encouraging results.^[3]^[4]

Allylestrenol is sold under several trade names, including Gestin, Turinal,Gestrenol, Gestanin, Gestanol or Gestanon, Maintaine, Orageston, and Profar. It is currently not marketed in the United States, United Kingdom, or Canada, but as of 2011^[update], is extensively used in Bangladesh,Japan, Russia, India, and much of Southeast Asia.^[1]

References

↑ ^1.0 ^1.1 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1.
↑ Cortés-Prieto J, Bosch AO, Rocha JA (1980). "Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor". Clinical Therapeutics. 3 (3): 200–8. PMID 7459930.
↑ Fukuoka H, Ishibashi Y, Shiba T, Tuchiya F, Sakanishi S (July 1993). "[Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese). 39 (7): 679–83. PMID 7689782.
↑ Noguchi K, Takeda M, Hosaka M, Kubota Y (May 2002). "[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese). 48 (5): 269–73. PMID 12094708.

[Martindale-1] 1.0 ^1.1 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN 978-0-85369-840-1.

[2] Cortés-Prieto J, Bosch AO, Rocha JA (1980). "Allylestrenol: three years of experience with Gestanon in threatened abortion and premature labor". Clinical Therapeutics. 3 (3): 200–8. PMID 7459930.

[3] Fukuoka H, Ishibashi Y, Shiba T, Tuchiya F, Sakanishi S (July 1993). "[Clinical study of allylestrenol (Perselin) on patients with prostatic hypertrophy]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese). 39 (7): 679–83. PMID 7689782.

[4] Noguchi K, Takeda M, Hosaka M, Kubota Y (May 2002). "[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]". Hinyokika Kiyo. Acta Urologica Japonica (in Japanese). 48 (5): 269–73. PMID 12094708.

[1]

[2]

[3]

[4]

Clinical data

Synonyms	17α-Allylestr-4-en-17β-ol
Pregnancy category	Used in threatened miscarriage and RPL
ATC code	G03DC01 (WHO)
Identifiers
IUPAC name (17β)-17-(prop-2-en-1-yl)estr-4-en-17-ol
CAS Number	432-60-0^Y
PubChem CID	235905
DrugBank	DB01431^Y
ChemSpider	205855^Y
UNII	I47VB5DZ8O
KEGG	D01374^Y
ChEMBL	ChEMBL1445549^N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₁H₃₂O
Molar mass	300.48 g/mol
3D model (JSmol)	Interactive image
SMILES O[C@]2(CC[C@H]1[C@H]4[C@H](CC[C@@]12C)[C@@H]3\C(=C/CCC3)CC4)C\C=C
InChI InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1^Y Key:ATXHVCQZZJYMCF-XUDSTZEESA-N^Y
^NY (what is this?) (verify)

Allylestrenol

Overview

References

Navigation menu